Johnson & Johnson (JNJ) will withdraw the LINC Reflux Management System from markets outside the U.S. by March 2026. The device treats chronic gastroesophageal reflux disease, with the U.S. market unaffected. Guggenheim raised JNJ’s price target from $167 to $206, citing strong growth and potential sales of new drugs. JNJ operates globally in pharmaceuticals, medical devices, and consumer health markets.

Read more at Yahoo Finance: Johnson & Johnson (JNJ) to Withdraw the LINC Reflux Management System from Markets Outside the U.S.